Keywords: MITT; Mild; Moderate; Asthma; Lebrikizumab; AE; adverse event; AQLQ(S); Standardised Asthma Quality of Life Questionnaire; ATA; anti-therapeutic antibodies; FeNO; fractional exhaled nitric oxide; FEV1; forced expiratory volume in 1â¯s; HLGT; high level group t
مقالات ISI MITT (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: MITT; AEs; adverse events; ITT; intention-to-treat; MedDRA; Medical Dictionary for Regulatory Activities; MITT; modified intention-to-treat; MPP; modified per-protocol; PP; per-protocol; PT; preferred term; SD; standard deviation; SOC; system organ class; Otomy
Keywords: MITT; The trial was registered under NCT02433834 at; http://www.clinicaltrials.gov; Asthma; Co-suspension delivery technology; Glycopyrronium; Inhaled corticosteroid use; Metered dose inhaler; ACQ-5; Asthma Control Questionnaire-5; AE; adverse event; AUC0-3;
Keywords: MITT; AIHQ; Ambiguous Intentions Hostility Questionnaire; ER-40; Emotion Recognition-40 task; Eyes Test; Reading the Mind in the Eyes Test; GSS; Global social skill; IU; International Units; mITT; Modified intention-to-treat; NVSS; Nonverbal social skill; PANSS
Keywords: MITT; ABL-SC; subcutaneous abaloparatide; ACTIVE; Abaloparatide Comparator Trial In Vertebral Endpoints; ACTIVExtend; extension trial of the Abaloparatide Comparator Trial In Vertebral Endpoints; AE; adverse event; ALN; alendronate; BMD; bone mineral density; F
Keywords: MITT; Allergen challenge; allergen peptides; allergy; allergic rhinoconjunctivitis; allergic rhinitis; environmental exposure unit; epitope; grass; immunotherapy; synthetic peptide immunoregulatory epitope; AE; Adverse events; AIT; Allergen immunotherapy; ARC;
Keywords: MITT; Omalizumab; Urticaria; Chronic spontaneous; Chronic idiopathic; Itch; Hive; Pruritus; Wheal; Antihistamine; AE; Adverse event; CI; Confidence interval; CIU; Chronic idiopathic urticaria; CSU; Chronic spontaneous urticaria; CU; Chronic urticaria; DLQI; Der
Keywords: MITT; BMI; body mass index; HbA1c; hemoglobin A1c; mITT; modified intention-to-treat analysis; PN; pen needle; T1DM; type 1 diabetes mellitus; T2DM; type 2 diabetes mellitus; TDD; total daily dose (of insulin);
Keywords: MITT; Helicobacter pylori; Treatment; Quadruple Therapy; Review; Treatment Success; Concomitant Therapy; Sequential Therapy; Bismuth; Clarithromycin; Tetracycline; Metronidazole; Amoxicillin; Proton Pump Inhibitors; Evidence Based; ITT; intention to treat; MITT
Keywords: MITT; Asthma; lebrikizumab; IL-13; type 2 inflammation; periostin; uncontrolled; antibody; FEV1; AE; Adverse event; Feno; Fraction of exhaled nitric oxide; HR; Hazard ratio; ICS; Inhaled corticosteroid; mITT; Modified intent-to-treat; PEF; Peak expiratory flow;
A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial
Keywords: MITT; Clinical trial conduct; Bayesian inference; Electronic case report form; Safety; Multidisciplinary; AE; adverse events; AUC; area under the curve; BCP; bevacizumab, carboplatin and paclitaxel; CP; carboplatin and paclitaxel; CRA; clinical research associa
Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease
Keywords: MITT; Co-suspension delivery technology; Formoterol fumarate dihydrate; Glycopyrronium; Metered dose inhaler; Spacer; Valved holding chamber; AE; adverse event; ANOVA; analysis of variance; AUC0-12; area under the curve from 0 to 12â¯h; BMI; body mass index;
A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines
Keywords: MITT; ADR; Adverse Drug Reaction; AE; Adverse Event; CI; Confidence Interval; CV; Coefficient of Variation; GAVI; Gavi, The Vaccine Alliance; GMR; Geometric Mean Ratio; GMT; Geometric Mean Titer; GTFCC; Global Task Force for Cholera Control; IRB; Institutional
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
Keywords: MITT; ACMG; American College of Medical Genetics and Genomics; ADHD RS-IV IA; Attention Deficit Hyperactivity Disorder Rating Scale IV, inattention subscore; AE; adverse event; ANCOVA; analysis of covariance; CANTAB; Cambridge Neuropsychological Test Automated
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India
Keywords: MITT; DAA; Direct Acting Antiviral; DCV; Daclatasvir; EASL; European Association of Study of the Liver (EASL); ETR; End of Treatment Response; HBV; Hepatitis B; HCC; Hepatocellular Carcinoma; HCV; Hepatitis C Virus; HIV; Human Immunedeficiency Virus; ITT; inten
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease
Keywords: MITT; Combined Remission; Clinical Remission; Anal Fistula; Cell Therapy; CDAI; Crohn's Disease Activity Index; CI; confidence interval; Cx601; allogeneic; expanded; adipose-derived stem cells; IBDQ; inflammatory bowel disease questionnaire; LOCF; last observ
Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: AÂ randomized controlled study
Keywords: MITT; Asthma; viral infection; inflammation; Toll-like receptor 3; ACQ7; Asthma Control Questionnaire 7; AE; Adverse event; AUC; Area under the curve; CCSS; Cold and Chest Symptom Scale; CSAS; Cold Symptom Assessment Score; Feno; Fraction of exhaled nitric oxid
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: MITT; Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month ex
Keywords: MITT; Glycaemic control; Hypoglycaemia; Insulin glargine; Type 2 diabetes; AE; adverse event; ANCOVA; analysis of covariance; BL; baseline; BMI; body mass index; CI; confidence interval; FPG; fasting plasma glucose; Gla-100; glargine 100; Gla-300; glargine 300;
Oral Triiodothyronine for Infants and Children Undergoing Cardiopulmonary Bypass
Keywords: MITT; CAVC; complete atrioventricular canal; CI; confidence interval; CoA; coarctation of the aorta; CPB; cardiopulmonary bypass; ESS; euthyroid sick syndrome; FT3; free T3; HR; hazard ratio; IAA; interrupted aortic arch; LOS; length of stay; ICU; intensive car
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
Keywords: MITT; AJCC; American Joint Committee on Cancer; ANA; antinuclear antibody; CI; confidence intervals; EGFR; epidermal growth factor; HR; hazard ratio; ISR; injection site reactions; ITT; intent-to-treat; mITT; modified intent-to-treat; MUC1; mucin 1; NSCLC; non-
Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials
Keywords: MITT; AED; antiepileptic drug; ALT; alanine aminotransferase; CBZ; carbamazepine; CI; confidence interval; DRESS; drug reaction with eosinophilia and systemic symptoms; ESL; eslicarbazepine acetate; GCP; Good Clinical Practice; mITT; modified intent-to-treat; M
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Keywords: MITT; antiplatelet therapy; bleeding; coronary artery disease; outcomes; CHAMPION; Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition; CI; confidence interval; GPI; glycoprotein IIb/IIIa inhibitor; GUSTO; Global Use of Strate
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial
Keywords: MITT; 5-FU; 5-fluorouracil; AE; adverse event; CI; confidence interval; CR; complete response; CRT; chemoradiotherapy; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology Group; KPS; Karnofsky Performance Status; mITT; modified intention to treat; m
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease
Keywords: MITT; Pathology; Healing; Inflammation; Treatment; AE; adverse events; ANCOVA; analysis of covariance; CDSD; celiac disease symptom diary; DGP; deamidated gliadin peptide; GFD; gluten-free diet; GI; gastrointestinal; ICDSQ; Impact of Celiac Disease Symptoms Que
Visual Field Change and 24-Hour IOP-Related Profile with a Contact Lens Sensor in Treated Glaucoma Patients
Keywords: MITT; CLS; contact lens sensor; GAT; Goldmann applanation tonometry; IOP; intraocular pressure; MD; mean deviation; mITT; modified intent-to-treat; PLS; partial least squares;
Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis
Keywords: MITT; RM-131; Phase 2 Trial; Gastrointestinal Motility; Dose Comparison; ADA; antidrug antibody; AE; adverse event; ANCOVA; analysis of covariance; DGSSD; Diabetic Gastroparesis Symptom Severity Diary; ECG; electrocardiogram; GCSI-DD; Gastroparesis Cardinal Sym
Efficacy of 2Â months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study
Keywords: MITT; Allergen-specific immunotherapy; birch pollen allergy; Bet v 1; contiguous overlapping peptides; synthetic peptides; aluminum hydroxide; IgG4; IgE; desensitization; clinical trial; AE; Adverse event; AIT; Allergen-specific immunotherapy; ANCOVA; Analysis
Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure
Keywords: MITT; IOP; intraocular pressure; mITT; modified intent to treat; OAG; open-angle glaucoma; OHT; ocular hypertension;
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults
Keywords: MITT; Staphylococcus aureus; Vaccine; Functional antibodies; Capsule proteins; Clinicaltrials.gov Identifier. NCT01018641; AE; adverse event; ClfA; clumping factor A; cLIA; competitive Luminex® immunoassay; CP; capsular polysaccharide; CP5; capsular polysaccha
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])
Keywords: MITT; bivalirudin; cangrelor; CHAMPION PHOENIX; stent thrombosis; CI; confidence interval; GUSTO; Global Use of Strategies to Open Occluded Arteries; IDR; ischemia-driven revascularization; MI; myocardial infarction; mITT; modified intention-to-treat; NSTE-ACS;
Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: Results of an open label study
Keywords: MITT; AE; adverse event; CI; confidence interval; GMT; geometric mean titre; GMR; GMT ratio; hSBA; serum bactericidal activity assay with human complement; MITT; modified intent-to-treat; SAE; serious adverse event; Meningococcal disease; Immunogenicity; Safety
Research ArticleSwitching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Keywords: MITT; ALT; alanine aminotransferase; CHB; chronic hepatitis B; CI; confidence interval; ETV; entecavir; HBeAg; hepatitis B e antigen; HBsAg; hepatitis B surface antigen; HBV; hepatitis B virus; ITT; intention-to-treat; mITT; modified intention-to-treat; NA; nuc
Research ArticleBoceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
Keywords: MITT; HCV; hepatitis C virus; BOC; boceprevir; PR; peginterferon with ribavirin; SVR; sustained virological response; TW; treatment week; NS3/4A; nonstructural proteins 3 and 4A; IU/ml; international units per milliliter; mITT; modified intent-to-treat; ITT; in
Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study
Keywords: MITT; Meningococcal disease; Japanese encephalitis; Rabies; Vaccine; Co-administration; AE; adverse event; CI; confidence interval; GMC; geometric mean concentration; GMT; geometric mean titer; hSBA; serum bactericidal activities with human complement; JE; Japa
Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
Keywords: MITT; Clinical Trial; Fibrosis; Direct-Acting Antiviral Agent; HCV; hepatitis C virus; LLQ; lower limit of quantification; mITT; modified intention-to-treat; P/R; peginterferon alfa and ribavirin; RAV; resistance-associated variants; RVR; rapid virologic respon
Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study
Keywords: MITT; Birth cohort; double-blind randomized trial; nutritional intervention; cow's milk protein hydrolysate infant formulas; long-term allergy prevention; AD; Atopic eczema/dermatitis; AM; Allergic manifestation; aRR; Adjusted relative risk; CMF; Standard cow's
MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments
Keywords: MITT; AE; adverse event; Cmax; maximum concentration; DHE; dihydroergotamine mesylate; FEV1; forced expiratory volume in 1 second; ICHD-II; International Classification of Headache Disorders, 2nd edition; mITT; modified intent-to-treat;
TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Keywords: MITT; AE; adverse event; CI; confidence interval; CRBSI; catheter-related bloodstream infection; CVC; central venous catheter; DVT; deep vein thrombosis; ICH; intracranial hemorrhage; MITT; modified intent-to-treat; PBO-TNK-TNK; placebo, tenecteplase, and tenec
A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Keywords: MITT; HRS; hepatorenal syndrome; MELD; Model for End-Stage Liver Disease; MITT; modified intention-to-treat; SCr; serum creatinine;
Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis
Keywords: MITT; AE; Adverse event; ANOVA; Analysis of variance; BMI; Body mass index; CF; Cystic fibrosis; CFA; Coefficient of fat absorption; CFQ-R; Cystic Fibrosis Questionnaire-Revised; CNA; Coefficient of nitrogen absorption; ITT; Intention to treat; mITT; Modified